gadoteridol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diagnostic agents, gadolinium derivatives 1268 120066-54-8

Description:

MoleculeDescription

Synonyms:

  • gadoteridol
  • Gadolinium-HP-DO 3A
  • ProHance
nonionic magnetic resonance contrast agent; structure given in first source
  • Molecular weight: 557.68
  • Formula: C17H28GdN4O7
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.50 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.60 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 737 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Nov. 16, 1992 FDA BRACCO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 668.16 46.23 115 2743 3993 90621596
Skin hypertrophy 273.20 46.23 53 2805 3557 90622032
Skin induration 259.86 46.23 50 2808 3212 90622377
Skin tightness 220.57 46.23 46 2812 4442 90621147
Anaphylactic reaction 137.46 46.23 63 2795 87461 90538128
Contrast media deposition 118.28 46.23 15 2843 51 90625538
Skin fibrosis 118.12 46.23 21 2837 867 90624722
Fibrosis 117.50 46.23 29 2829 5923 90619666
Contrast media reaction 117.25 46.23 22 2836 1229 90624360
Scar 90.24 46.23 29 2829 15366 90610223
Skin hyperpigmentation 89.36 46.23 24 2834 6827 90618762
Anhedonia 85.72 46.23 26 2832 11405 90614184
Emotional distress 78.93 46.23 33 2825 36629 90588960
Anaphylactic shock 73.27 46.23 30 2828 31587 90594002
Skin discolouration 69.76 46.23 32 2826 44283 90581306
Peau d'orange 68.33 46.23 10 2848 116 90625473
Joint contracture 58.30 46.23 13 2845 1709 90623880
Pruritus 47.76 46.23 71 2787 541454 90084135
Muscle tightness 46.23 46.23 17 2841 13422 90612167

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 561.70 56.99 102 1806 3399 42616028
Skin induration 206.08 56.99 40 1868 1887 42617540
Skin tightness 182.65 56.99 37 1871 2173 42617254
Skin hypertrophy 179.80 56.99 38 1870 2751 42616676
Contrast media deposition 174.61 56.99 22 1886 43 42619384
Fibrosis 121.58 56.99 28 1880 3002 42616425
Joint contracture 119.47 56.99 26 1882 2155 42617272
Joint range of motion decreased 117.93 56.99 33 1875 7720 42611707
Skin fibrosis 103.28 56.99 20 1888 927 42618500
Scar 99.57 56.99 28 1880 6660 42612767
Extremity contracture 88.22 56.99 17 1891 767 42618660
Deformity 87.18 56.99 19 1889 1583 42617844
Emotional distress 79.09 56.99 29 1879 16064 42603363
Anhedonia 74.27 56.99 23 1885 7617 42611810
Mobility decreased 72.19 56.99 34 1874 35272 42584155
Contrast media reaction 70.68 56.99 15 1893 1101 42618326
Pain 60.64 56.99 64 1844 244784 42374643

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 746.56 53.04 134 3722 5349 110580094
Skin hypertrophy 361.86 53.04 72 3784 4975 110580468
Skin induration 341.12 53.04 67 3789 4328 110581115
Skin tightness 318.93 53.04 66 3790 5547 110579896
Contrast media deposition 265.53 53.04 33 3823 79 110585364
Contrast media reaction 182.59 53.04 36 3820 2362 110583081
Anaphylactic reaction 179.95 53.04 85 3771 114215 110471228
Skin fibrosis 169.24 53.04 31 3825 1369 110584074
Fibrosis 155.92 53.04 39 3817 7603 110577840
Joint contracture 133.91 53.04 28 3828 2463 110582980
Scar 133.79 53.04 41 3815 16840 110568603
Anhedonia 99.41 53.04 32 3824 15396 110570047
Skin hyperpigmentation 99.12 53.04 28 3828 8668 110576775
Anaphylactic shock 89.22 53.04 41 3815 51505 110533938
Emotional distress 88.19 53.04 39 3817 44808 110540635
Peau d'orange 87.30 53.04 14 3842 276 110585167
Skin discolouration 84.84 53.04 39 3817 49007 110536436
Joint range of motion decreased 80.29 53.04 51 3805 121781 110463662
Shock 69.57 53.04 35 3821 53553 110531890
Deformity 69.25 53.04 22 3834 10138 110575305
Joint stiffness 67.58 53.04 37 3819 67206 110518237
Extremity contracture 67.57 53.04 15 3841 1746 110583697
Burning sensation 58.49 53.04 34 3822 69178 110516265
Pruritus 56.20 53.04 84 3772 581476 110003967

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08CA04 VARIOUS
CONTRAST MEDIA
MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Paramagnetic contrast media
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA MoA N0000175862 Magnetic Resonance Contrast Activity
FDA EPC N0000180184 Paramagnetic Contrast Agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:37335 MRI contrast agent

Related Drugs by ATC class:

V08CA Paramagnetic contrast media 10 drugs
gadobenic acidgadobutrolgadodiamidegadofosvesetgadopentetate dimegluminegadopiclenolgadoteric acidgadoversetamidegadoxetic acidmangafodipir

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4020572 VUID
N0000148274 NUI
D01137 KEGG_DRUG
4020572 VANDF
C0060930 UMLSCUI
CHEBI:31643 CHEBI
CHEMBL1200593 ChEMBL_ID
DB00597 DRUGBANK_ID
C062402 MESH_SUPPLEMENTAL_RECORD_UI
60714 PUBCHEM_CID
6655 INN_ID
0199MV609F UNII
25483 RXNORM
396248 MMSL
4220 MMSL
4773 MMSL
d03843 MMSL
004118 NDDF
353946009 SNOMEDCT_US
420600009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ProHance HUMAN PRESCRIPTION DRUG LABEL 1 0270-1111 INJECTION, SOLUTION 279.30 mg INTRAVENOUS NDA 22 sections
ProHance HUMAN PRESCRIPTION DRUG LABEL 1 0270-1111 INJECTION, SOLUTION 279.30 mg INTRAVENOUS NDA 22 sections
GADOTERIDOL HUMAN PRESCRIPTION DRUG LABEL 1 70436-121 INJECTION 279.30 mg INTRAVENOUS ANDA 27 sections